| __timestamp | ImmunityBio, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 1595000 | 242549000 |
| Thursday, January 1, 2015 | 11434000 | 245098000 |
| Friday, January 1, 2016 | 26546000 | 147600000 |
| Sunday, January 1, 2017 | 39778000 | 264600000 |
| Monday, January 1, 2018 | 53418000 | 357900000 |
| Tuesday, January 1, 2019 | 111997000 | 1182600000 |
| Wednesday, January 1, 2020 | 139507000 | 357700000 |
| Friday, January 1, 2021 | 195958000 | 540100000 |
| Saturday, January 1, 2022 | 248149000 | 322900000 |
| Sunday, January 1, 2023 | 232366000 | 408000000 |
Unleashing insights
In the ever-evolving world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, United Therapeutics Corporation and ImmunityBio, Inc. have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, United Therapeutics consistently allocated a significant portion of its resources to R&D, peaking in 2019 with a staggering 1.18 billion dollars. This represents a nearly 400% increase from its 2016 spending. In contrast, ImmunityBio's R&D expenditure, while growing, remained more modest, reaching its highest point in 2022 with approximately 248 million dollars, a 15-fold increase from 2014. This data highlights United Therapeutics' aggressive strategy in pioneering new treatments, while ImmunityBio's steady growth reflects a more cautious yet progressive approach. As the biotech landscape continues to shift, these spending patterns offer valuable insights into each company's strategic priorities.
Merck & Co., Inc. or United Therapeutics Corporation: Who Invests More in Innovation?
Comparing Innovation Spending: Regeneron Pharmaceuticals, Inc. and ImmunityBio, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and United Therapeutics Corporation
R&D Insights: How United Therapeutics Corporation and Incyte Corporation Allocate Funds
United Therapeutics Corporation vs Ascendis Pharma A/S: Strategic Focus on R&D Spending
R&D Insights: How United Therapeutics Corporation and ADMA Biologics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for United Therapeutics Corporation and Arrowhead Pharmaceuticals, Inc.
Analyzing R&D Budgets: Bio-Techne Corporation vs ImmunityBio, Inc.
Ultragenyx Pharmaceutical Inc. or ImmunityBio, Inc.: Who Invests More in Innovation?
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Amicus Therapeutics, Inc. vs ImmunityBio, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for ImmunityBio, Inc. and BioCryst Pharmaceuticals, Inc.